Clinical Trials Logo

Clinical Trial Summary

Investigation on how robotically mediated sensorimotor stimulation induces and triggers presence hallucinations in patients with Parkinson disease


Clinical Trial Description

Parkinson's Disease (PD) is primarily known and characterized by motor symptoms such as tremor, rigidity and bradykinesia. However, a significant number of non-motor symptoms also accompany the unfolding of this disease. In fact, hallucinations are experienced by approximately 60% of the patients. The most common and amongst one of the earliest hallucinations in Parkinson's Disease, is the Presence Hallucination (PH), i.e., the strange sensation of perceiving someone behind when no one is actually there. In the present study the researchers aim at investigating the behavioural and neural mechanisms underlying symptomatic PH in PD. To do so the researchers intend to induce the PH in a repeated and controlled manner in the MRI scanner, with an extensively verified paradigm which gives rise to this sensation by means of robotically-mediated sensorimotor stimulation. This setup has in fact been shown to trigger the occurrence of symptomatic PH in these patients. The possibility to induce PH while the patient is in the MRI will allow the researchers to investigate online the brain networks associated with it.

With analysis on the fine brain connectivity changes during PH-induction, the investigators intend to pinpoint the exact mechanism behind the appearance of this hallucination in these patients, in a similar fashion to previous work with the PH-induction in healthy individuals. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04579887
Study type Interventional
Source Ecole Polytechnique Fédérale de Lausanne
Contact Olaf Blanke
Phone +41 21 693 9621
Email olaf.blanke@epfl.ch
Status Recruiting
Phase N/A
Start date August 17, 2020
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05824728 - Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis Phase 2
Terminated NCT03152292 - The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Withdrawn NCT05344365 - A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis Phase 2
Recruiting NCT05357612 - Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Phase 4
Completed NCT06450184 - Bioequivalence Study of Pimavanserin 34 mg Capsule Phase 1
Completed NCT04292223 - Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis Phase 4
Completed NCT02969369 - A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Phase 2
Not yet recruiting NCT05995782 - A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 Phase 1
Recruiting NCT04592965 - Hallucinations in Parkinson's Disease N/A
Completed NCT05240339 - Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Recruiting NCT03661125 - SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis Early Phase 1